论文部分内容阅读
目的 :探讨乳腺癌中抑制转移基因nm23的表达及其与C erbB 2、ER、PR以及肿瘤组织学分级、淋巴结转移等临床病理特性的相互关系。方法 :应用免疫组化SP法检测70例乳腺癌中nm23蛋白、C erbB 2蛋白、ER、PR的表达。结果 :乳腺癌中nm23蛋白阳性率为62.86 % ,nm23蛋白的表达与组织学分级、细胞核分级、淋巴结转移以及临床分期均有相关性(P<0.01) ,但与C erbB 2蛋白、ER、PR表达情况无明显相关性。有淋巴结转移组nm23蛋白阳性率为39.47% ,C erbB 2蛋白阳性率为63.16%(P<0.05) ,而nm23蛋白阴性、同时C erbB 2蛋白阳性组的淋巴结转移率为93.33%。结论 :乳腺癌组织中nm23蛋白、C erbB 2蛋白表达情况能提示肿瘤的转移和预后。
OBJECTIVE: To investigate the expression of nm23 in breast cancer and its relationship with clinicopathological features such as C erbB 2, ER, PR, tumor histological grade and lymph node metastasis. Methods: The expressions of nm23 protein, C erbB 2 protein, ER and PR in 70 cases of breast cancer were detected by immunohistochemical SP method. Results: The positive rate of nm23 protein in breast cancer was 62.86%. The expression of nm23 protein was correlated with histological grade, nuclear grade, lymph node metastasis and clinical stage (P <0.01), but not with C erbB 2 protein, ER, PR No significant correlation between expression. The positive rate of nm23 protein in lymph node metastasis was 39.47%, the positive rate of C erbB 2 protein was 63.16% (P <0.05), while the nm23 protein was negative, while the rate of lymph node metastasis in positive C erbB 2 protein was 93.33%. Conclusion: The expression of nm23 protein and C erbB 2 protein in breast cancer can be indicative of tumor metastasis and prognosis.